Kawasaki syndrome

Immunoglobulin obtained from pooled plasma obtained from hepatitis B and HIV negative donors is used as an aspecific immunostimulant in immunodeficiency diseases, idiopathic thrombocytopenia, autoimmune hemolytic anemias, Kawasaki syndrome and to prevent infections in immune compromised patients with leukemia or multiple myeloma. Adverse effects include potentially severe hypersensitivity reactions. 

Intravenous gamma globulin preparations are available for replacement therapy for patients with congenital agammaglobulinaemia and hypogammag-lobulinaemia, idiopathic thrombocytopenic purpura and Kawasaki syndrome. It is also used for prophylaxis of infection following bone marrow transplantation. 

Mucocutaneous lymph node syndrome (Kawasaki syndrome)... 

Mucocutaneous eruption (1999) Edwards SG +, Postgrad Med J 75, 680 (1993) Konishi T +, Eur J Pediatr I 52, 605 Mucocutaneous lymph node syndrome (Kawasaki syndrome)... 

Contraindication in a susceptible subpopulation Aspirin (acetylsalicylic acid) has been associated with the occurrence of Reye syndrome and, as a result, the Committee on Safety of Medicines has advised that aspirin-containing preparations should not be given to children and adolescents under 16 years of age unless specifically indicated, for example for Kawasaki syndrome. Establishing this contraindication, relating to what is probably the most widely used medicine known, involved educating the whole community and represented one of the most remarkable therapeutic achievements of the late twentieth century. The... 

Leung DY, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993 342 1385-1388. 

Leung DY, Giorno RC, Kazemi LV Flynn PA, Busse JB Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol 1995 155 5018-5021. 

Sato K, Ouchi K, Taki M Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome. Pediatr Infect Dis 1983 2 123-126. 

SHraishi T, Yamamoto T. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome. Pediatr Dermatol 2013 May-Jun 30(3) e30-1. 

Suggested Alternatives for Differential Diagnosis Anthrax, brucellosis, dengue, ehrlichiosis, infectious mononucleosis, Kawasaki disease, leptospirosis, malaria, meningitis, men-ingococcemia, relapsing fever, Rocky Mountain spotted fever, syphilis, toxic shock syndrome, toxoplasmosis, tularemia, typhoid fever, rubella, measles. 

Kawasaki disease (mucocutaneous iymph node syndrome) For acute febrile period, 80 to 180 mg/kg/day very high doses may be needed to achieve therapeutic levels. After the fever resolves, dosage may be adjusted to 10 mg/kg/day. 

Hashimoto, O., Shimizu, Y., and Kawasaki, Y. (1993) Low frequency of the fragile X syndrome among Japanese autistic subjects. / Autism Dev Disord 23 201-209. 

A Kawasaki-Uke syndrome has been reported in a patient taking sulfasalazine, who later reacted in the same way to mesalazine (SEDA-16, 427). 

Amita DB, Danon YL, Garty BZ. Kawasaki-like syndrome associated with griseofulvin treatment. Clin Exp Dermatol... 

Intravenous immune globulin (IVIG) Human IgG - Primary immunodeficiency syndromes - Kawasaki disease - Acute renal failure 103,106-108... 

Other situations Situations such as a pheochro-mocytomaand coronary arteritis secondary to systemic diseases, as Takayasu s disease, Kawasaki s disease, Churg-Strauss syndrome, etc., may generate myocardial ischaemia, ACS and even a myocardial infarction. This is also the case for patients with AIDS that often present diffuse and severe atherosclerotic lesions. 

Kawasaki disease (mucocutaneous lymph node syndrome). 

Kawakami T, Fujita A, Takeuchi S, Muto S, Soma Y. Drug-induced hypersensitivity syndrome drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease. J Am Acad Dermatol 2009 60(1) 146-9. 

Sato T, Kawasaki Y, Waragai T, Imaizumi T, Ono A, SakaiN, et al. Relapse of minimal change nephrotic syndrome after intravitreal bevad-zumab. Pediatr Int 2013 55(3) e46-8. 

---